Literature DB >> 28685077

Effect of treatment support on preventing local recurrence of hepatocellular carcinoma directly adjacent to the diaphragm.

Toru Ishikawa1, Michitaka Imai1, Masayoshi Ko1, Hiroki Sato1, Yujiro Nozawa1, Tomoe Sano1, Akito Iwanaga1, Keiichi Seki1, Terasu Honma1, Toshiaki Yoshida1.   

Abstract

Treatment support is anticipated to improve the results of radiofrequency ablation (RFA) treatment in cases in which visualization of tumors using the conventional B-mode is unclear. In the present study, the effectiveness of treatment support for RFA reducing the local recurrence rate of hepatocellular carcinoma (HCC) that are located directly adjacent to the diaphragm, and which are difficult to visualize with B-mode ultrasound imaging, was investigated. A total of 103 HCC tumors measuring <5 cm, which were located abutting the diaphragm, and which were difficult to visualize using the B-mode, were treated using RFA. Thirty-three of those HCC tumors were treated using RFA without treatment support, whereas the remaining 70 HCC tumors were treated using RFA with treatment support, including artificial pleural effusion, contrast-enhanced ultrasonography (CEUS) with the contrasting agent, Sonazoid™, and fusion imaging, either alone or in combination to improve the visualization of the tumors. The rate of local recurrence, and factors affecting local recurrence, were analyzed. Local recurrences were confirmed in 17 of the 103 nodules (16.50%). The overall rate of local recurrence was 13.1% at 6 months, and 20.2% at 12 months. The rate of local recurrence using RFA with artificial pleural effusion was significantly lower compared with those cases of HCC tumors treated without artificial pleural effusion (P=0.008). Similarly, the rate of local recurrence for CEUS RFA with Sonazoid™ was significantly lower compared with those cases of HCC tumors treated without Sonazoid™ (P=0.00081). In a multivariate analysis, CEUS RFA with Sonazoid™ and artificial pleural effusion contributed to the decrease in the rate of local recurrence (hazard ratios, 0.075 and 0.143, respectively). Based on these results, it is possible to conclude that CEUS with Sonazoid™ as a treatment support was the most effective method for reducing the rate of local recurrences abutting the diaphragm that are difficult to visualize using B-mode ultrasonography.

Entities:  

Keywords:  Sonazoid™; hepatocellular carcinoma; radiofrequency ablation; treatment support

Year:  2017        PMID: 28685077      PMCID: PMC5492694          DOI: 10.3892/mco.2017.1257

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  27 in total

Review 1.  Treatment of hepatocellular carcinoma by interventional methods.

Authors:  T Livraghi
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

2.  Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome.

Authors:  Yasunori Minami; Masatoshi Kudo; Toshihiko Kawasaki; Hobyung Chung; Chikara Ogawa; Hitoshi Shiozaki
Journal:  AJR Am J Roentgenol       Date:  2004-05       Impact factor: 3.959

3.  Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm.

Authors:  Keiji Mita; Soo Ryang Kim; Masatoshi Kudo; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Katsumi Fukuda; Toshiyuki Matsuoka; Yoko Maekawa; Yoshitake Hayashi
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

4.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

5.  Characterization of tumor imaging with microbubble-based ultrasound contrast agent, sonazoid, in rabbit liver.

Authors:  Rira Watanabe; Manabu Matsumura; Chun-Jen Chen; Yuki Kaneda; Masayoshi Fujimaki
Journal:  Biol Pharm Bull       Date:  2005-06       Impact factor: 2.233

6.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

7.  Influence of an artificial pleural effusion technique on cardio-pulmonary function and autonomic activity.

Authors:  Hiroshi Fukuno; Katsuyoshi Tamaki; Mari Urata; Nao Kohno; Ichiro Shimizu; Masahiro Nomura; Susumu Ito; Ken Saito
Journal:  J Med Invest       Date:  2007-02

8.  Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Arrigo Battocchia; Angelo Tonon; Girolamo Fracastoro; Claudio Cordiano
Journal:  Hepatogastroenterology       Date:  2003 Mar-Apr

9.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

10.  Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Lawrence E Harrison; Baburao Koneru; Phil Baramipour; Adrian Fisher; Alison Barone; Dorian Wilson; Andrew Dela Torre; Kyunghee C Cho; Daniel Contractor; Maria Korogodsky
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

View more
  1 in total

1.  Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma.

Authors:  Min Hwan Kwak; Min Woo Lee; Seong Eun Ko; Hyunchul Rhim; Tae Wook Kang; Kyoung Doo Song; Jong Man Kim; Gyu-Seong Choi
Journal:  Ultrasonography       Date:  2022-02-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.